Endocrinology
From the Journals
Vitamin D shows no survival benefit in nondeficient elderly
“This is not dissimilar to research with many other nutrients showing that increasing intake above the adequate intake has no further health...
Feature
Uptake uncertain for potent new LDL-lowerer inclisiran
Inclisiran, a novel small interfering RNA drug that inhibits PCSK9, made its U.S. debut in early 2022 with cautious uptake prospects.
News
AHA advice for diabetes patients to stay heart healthy
Fewer than one in five Americans meet targets for blood sugar, blood pressure, and lipids.
News
COVID-19 linked to increased diabetes risk in youth
Two large databases indicate significantly increased diabetes risk among those with COVID-19 but not other acute respiratory illnesses.
News
ADA standards of care 2022: Screen more, personalize, use technology
The ADA’s new standards of care call for screening younger people and pregnant women earlier, along with furthering the trends toward...
Conference Coverage
SGLT2 inhibitor use tied to fewer atrial arrhythmias
From the Journals
Does vitamin D benefit only those who are deficient?
The results will “allow clinicians to better weigh the potential benefits of supplementation against its risk,” such as financial cost.
Conference Coverage
Empagliflozin a winner in challenging arena of stabilized acute HF
Early in-hospital initiation of SGLT2 inhibitors “should be considered the new standard of care” in most patients with heart failure regardless of...
Conference Coverage
EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients
From the Journals
Nondiabetes hospitalization is wrong time to up diabetes meds
Diabetes treatment intensification after being hospitalized for reasons other than diabetes was linked with a short-term increase in risk of...
From the Journals
Expensive insulins, pen devices dominate U.S. diabetes care
Analog insulins continue to represent more than 80% of prescriptions for type 2 diabetes in the U.S., despite rising costs and public scrutiny of...